Epithelial ovarian cancer (EOC) 
Introduction
Ovarian cancer is the fifth leading cause of cancer deaths among women in the Western world and has the highest mortality rate of all gynaecological cancers [1] . The 
Aberrant expression of miRNAs in ovarian cancer
Altogether eight groups [4] [5] [6] [7] [8] [9] [10] [11] [13] , was shown to be down-regulated in ovarian cancer [14, 15] and to inhibit cancer cell invasion [15] [17] , is a consensus miRNA specifically de-regulated in endometrioid carcinoma [6, 9] [6, 7] , while others used human immortalized ovarian surface epithelial (HIOSE) cell lines [4, 5, 8, 9, 11] [8] or SV40 virus [11] ; thus, it is not surprising that these two studies presented inconsistent and even conflict results. Additionally, primary cultured OSE cells [9] and, more recently, fallopian tube tissues [10] [6, 7] .
Regulation of microRNAs in ovarian cancer
Aberrant expression of miRNAs in human cancer can arise through several mechanisms, including genomic abnormalities, epigenetic factors, transcriptional regulation, mutations and polymorphisms (SNPs), and defects in the miRNA biogenesis machinery [19] . In EOC, the de-regulation of miRNAs can be caused partly by genomic abnormalities, since 37.1% of the genomic loci containing miRNA genes exhibit DNA number alterations by a array comparative genomic hybridization analysis, and miRNA copy number changes correlate with miRNA expression [4] . Epigenetic factors also directly impact miRNA expressions, and demethylating therapy has been shown to reverse hypermethylation and increase miRNA expression in EOC [5, 6] . In fact, genomic copy number loss and epigenetic silencing may account for the down-regulation of approximately 15% and at least 36% of miRNAs in advanced ovarian tumours, respectively [5] . In contrast, the overexpression of several miRNAs (miR-21, miR-203, miR-205) in vivo was thought to be caused by DNA hypomethylation [6] .
Functional genetic mutations in miRNA genes are very rare in EOC, as described by Bearfoot et al. [20] , who analysed 10 cancer-implicated miRNA genes for mutations in 90 EOC patients, and found no somatic mutations. Similarly, no miR-16-1 gene mutation were detected in 102 ovarian cancers [21] . However, a functional G to C single nucleotide polymorphism (SNP, rs2910164) within the pre-miR-146a sequence was identified in familial breast/ovarian cancers. The C containing allele increases mature miR-146a levels and creates a stronger match with the 3Ј-UTR of BRCA1, leading to an earlier age onset of familial breast and ovarian cancers [22] . miRNAs can also be regulated by transcriptional factors in EOC. A well-known example is p53, one of the most commonly mutated genes observed in EOC, which can robustly induce miR34b and miR-34c in OSE cells [23] . Hormones such as oestrogen, progesterone, androgens and gonadotrophins have all been implicated in the aetiology of EOC by initiating and repressing transcription of key genes [24, 25] [27, 28] . Given that both of these miRNAs are expressed in the OSE cells [6] , these miRNAs may be similarly regulated in these cells.
Mature miRNA biogenesis is dependent on their processing enzymes, including two key RNase III enzymes, Dicer and Drosha [29] . Given that miRNA expressions are globally down-regulated in EOC, it is conceivable that the levels of Dicer and Drosha may also be decreased. However, Drosha or Dicer showed no significant differences [5] or even higher expression levels [30] [5] . Similarly, Drosha and Dicer expression levels showed no significant difference between primary and recurrent ovarian cancers, although multiple miRNAs were de-regulated [31] . 
Biological function of miRNAs in epithelial ovarian cancer

Down-regulation of let-7: an early event during EOC initiation
Let-7 is the consensus miRNA down-regulated in almost all the expression profile studies in EOC [4] [5] [6] [7] [8] [9] [10] [11] . The let-7 family is comprised 12 family members located on 8 different chromosomes with identical seed sequences [32] . As [34] . This is further evidenced by the fact that the expression of the let-7 target gene, HMGA2, is higher in primary EOC tissues, but shows no difference between primary and metastastic sites [32] .
A puzzle in EOC carcinogenesis is the apparent 'differentiating up' instead of 'de-differentiation', as EOCs morphologically resemble more committed epithelial phenotypes compared to uncommitted OSE cells [35] . This paradox has prompted the hypothesis which argues that EOCs may stem from the secondary mullerian system or the fallopian tube instead of OSE cells [36] . However, there is no direct experimental evidence to support this hypothesis. Recently, putative ovarian tumour initiating cells were found by several investigators [37] [38] [39] [40] .
Multiple miRNAs as modulators of ovarian cancer cell proliferation
Multiple miRNAs may impact cancer cell proliferation and apoptosis during EOC initiation. The down-regulation of miR-143 [6, 7, 10] may promote cell proliferation via activation of the growth promoting proteins mitogen-activated protein kinase 7 (MAPK7) [41, 42] and KRAS [43] , while the loss of miR-125a/b activity [6, 7, 11] may inhibit cell apoptosis by elevating ERBB2 levels [44] , which are often seen in HG serous tumours. miR-21 [7, 10] and miR-214 [8, 9, 11] , overexpressed in EOC, may suppress phosphatase and tensin homologue (PTEN) activity [11, 45] in endometroid cancer, while up-regulation of miR-106 [4, 9, 10] and miR-20a [7, 9, 10] may promote cell growth by targeting p21/CDKN1A [46, 47] . Additionally, miR-34s, which are induced by p53, had been shown to promote cell cycle arrest, apoptosis and senescence by repression of multiple target genes such as Bcl-2, Cdk4 and CCDN1 [23] . This is of particular importance as p53 mutation is one of the most common genetic alterations observed in EOC, especially in HG serous tumours [48] . However, reduction in miR-34s may also be caused by a p53-independent mechanism in low-grade (LG) serous tumours. For example, miR-34a is located in 1p36, a locus that is frequently deleted in LG serous tumours [49] . Moreover, miR-34a was shown to be up-regulated by ELK-1 during BRAF induced senescence [50] , and mutation in BRAF has been described in 30~50% of LG serous tumours [48] . Thus, the loss of miR-34s could be one of the mechanisms used by both LG and
HG ovarian cancer cells to escape the control of a functioning p53 and BRAF and to survive oncogenic stimuli.
miR-199a and miR-9: link between tumour progression and chronic inflammation miR-9 is expressed at a low level in ovarian cancer tissues [6, 51] . miR-9 can directly target NF-B1, which is up-regulated in ovarian cancer [51] . In contrast, miR-199a can inhibit NF-B activity through suppression of its upstream activator, IKK␤ [16] . Suitably, miR-199a is also frequently de-regulated in EOC [6, 8] .
Inflammation accompanying each ovulation event can stress OSE cells such that they are disposed to genetic damage [52] . Inflammatory processes can also promote cancer progression through the production of multiple cytokines and chemokines [53] . [56] . Further studies indicated there are up to 50 potential target genes for miR-210, a majority of which are implicated in adaptation and cell survival under hypoxic stress [57] . Thus, hypoxia-mediated induction of miR-210 modulates the expression of genes promoting cell survival during stress, followed by tumour progression under favourable conditions. [9] can promote angiogenesis by directly repressing the anti-angiogenic factor TSP-1 [58] . [62] . [64, 65] . [6, 7, [9] [10] [11] 66] , down-regulated [8] or even unchanged [5] [67] [34] , and the down-regulation of miR-200, which regulates EMT and represses stemness [69, 70] [71] . miR-143 and miR-21/miR-214, may be involved in the LG pathway by targeting K-ras [43] and PTEN [11, 45] , which are frequently mutated in LG serous tumours [48] . Meanwhile, miR-125b and miR-146a may play a role in the HG grade pathway by repressing ERBB2 [41] and BRCA1 [22] . Figure 1 illustrates the proposed involvement of miRNAs in this complicated process.
As NF-B has a central role in the inflammatory response [53], it is possible that reduced expression of miR-199a and miR-9 work synergistically to promote an inflammatory environment by up-regulating NF-B protein levels, leading to ovarian cancer initiation and progression. In fact, it has been demonstrated that ovarian cancer cells with low miR-199a expression have the capacity to constitutively secrete pro-inflammatory cytokines [16]. Moreover, another important pro-inflammatory factor, COX-2, is known to be suppressed by miR-199a* [54]. This further highlights the importance of miR-199a in the inflammatory response.
HIF-miR-210 promotes cell adaptation during hypoxia
Hypoxia is a common feature of pathological conditions such as inflammation and solid tumours. Multiple hypoxic responses impacting cell survival are mediated through hypoxia-inducible transcription factors (HIFs). HIFs, along with transcriptional cofactors, bind to hypoxia response elements, modulating the expression of multiple target genes, including miRNAs important for angiogenesis and cell survival [55]. Among the 'hypoxiaresponsive' miRNAs, miR-210 has been reported to be the most prominent and consistent in ovarian cancer [56]. E2F transcription factor 3 (E2F3), a key protein in cell cycle, was directly targeted by miR-210 in EOC
In addition to miR-210, other miRNAs may participate in the hypoxia response by promoting tumour neo-angiogenesis. For example, the overexpression of miR-19a in ovarian cancer
miR-200 is a dynamic regulator during the transcoelomic metastasis of EOC
Although the expression of the miR-200 family miRNAs in ascites cells has not yet been examined, miR-200 expression was higher in stage I EOC compared to stage III EOC [63], indicating a downregulation of miR-200 before tumour metastasis. Moreover, it has also been shown that the mir-200 target, ZEB2, was expressed in cells isolated from effusions
Although there is clear evidence showing the miR-200 family to be metastasis suppressive, their expression in EOC is complex. miR-200s have been reported to be up-regulated
in EOC. This discrepancy may partly be due to technical issues, as whole ovaries were used as normal controls in some studies, and the majority of the cells within ovaries are stromal cells which lack miR-200 expression [61]. However, it is more likely that miR-200 could be both up-and down-regulated during EOC progression. miR-200 may be down-regulated early when cancer cells acquire invasive behaviour, but may also be up-regulated again during the re-epithelialization of distal metastases when cells undergo mesenchymal-toepithelial transition. Such stage specific regulation of miR-200 was partly demonstrated in a multistep tumorigenesis model, which showed that miR-200 began to be strongly down-regulated only when tumour progressed to metastasis
During ovarian cancer progression, miRNAs may facilitate tumour growth by promoting infiltration of inflammatory cells and inducing tumour angiogenesis or promoting cell adaptation during hypoxia. The dynamic expression of miR-200, which regulates EMT, may cause transcoelomic metastasis and ultimately macrometastasis formation of ovarian cancer. Therefore, multiple de-regulated miRNAs work synergistically during the initiation and multi-step progression of ovarian cancer.
miRNA as diagnostic and prognostic tools in ovarian cancer
In EOC, early-stage diagnosis is very difficult due to its insidious asymptomatic nature in early onset and the lack of sensitive and specific biomarkers. Until now mRNA or protein profiling in order to find ideal biomarkers has not achieved satisfying results. However, miRNA expression profiles seem to be a promising method, since profiling a few hundred miRNAs would have stronger predictive power for cancer diagnosis than profiling several tens of thousands of mRNAs or proteins [72] . In fact, a list of 29 miRNAs is able to classify breast tumours and normal tissues with an accuracy of 100% [73] [74] . The levels of plasma and serum miRNAs correlate strongly, suggesting that either plasma or serum can be used for investigation of these blood-based biomarkers [75] . Circulating miRNAs have been shown to be highly predictive of malignancy in colorectal cancer [76] , diffuse large B cell lymphoma [77] , and prostate cancer patients [74] [80] , lung cancer [81] , breast cancer [82] , colorectal cancer [83] and pancreatic cancer [84] . In ovarian cancer, the loss of let-7 and high expression of its target (HMGA2/let-7 ratio) was associated with unfavourable prognosis of ovarian cancer [32] . Similarly, reduced let-7i expression significantly increased the chemoresistance of ovarian cancer cells and was associated with the shorter progression-free survival [85] . More recently the prognostic value of miRNAs was studied by performing miRNA expression profiling analysis of 55 advanced ovarian tumours and correlating their expression level with cancer outcome [86] . Among the 96 cancer-related miRNAs, miR-200a was significantly associated with cancer survival. Elevated expression of miR-200 miRNAs predicted favourable outcomes [86] . However, inconsistent result was obtained by another group, who showed that tumours with higher miR-200a expression had poorer prognosis [7] . Moreover, miR-9 and miR-223 has been shown to be correlated with ovarian cancer recurrence [31] , which greatly impacts patient outcomes. These results suggest that miRNAs can be potentially important as biomarkers of EOC prognosis and provide evidence for tailored therapy.
Therapeutic potential of miRNAs in ovarian cancer
The potential usefulness of a miRNA-based therapy in cancer has been exploited by different approaches to increase or decrease expression of different miRNAs. For oncogenic miRNAs, miRNAs can be silenced by antisense oligonucleotides and antagomirs (synthetic analogues of miRNAs) [87, 88] . For tumour suppressive miRNAs, overexpression of miRNAs can be induced by using synthetic miRNA mimics, chemically modified oligonucleotides [89] , or adeno-associated virus based vector system [90] [11] . Forced expression of miR-200c can increase sensitivity to paclitaxel by targeting class III ␤-tubulin, whose expression is a common mechanism of resistance to microtubule-binding chemotherapeutic agents [91] . In fact, several reports indicate that ovarian cancer drug resistance is associated with a distinct miRNA fingerprint [63, 92, 93] 
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